科济药业(股票代码:02171)今日盘中股价大涨5.98%,引发市场关注。这主要得益于公司在CAR-T细胞疗法领域取得多项重大进展。
消息面上,科济药业宣布其自主研发的一款靶向CD19/CD20的通用型CAR-T细胞疗法KJ-C2219已在中国启动针对复发/难治性B细胞非霍奇金淋巴瘤的研究者发起临床试验。同时,公司代表性CAR-T产品舒瑞基奥仑赛注射液在关键II期临床试验中,针对晚期胃/食管胃结合部腺癌取得阳性数据。
这些进展标志着科济药业的CAR-T细胞疗法技术已取得重要突破,不仅能用于治疗血液系统癌症,也有望扩展至实体瘤领域。公司CAR-T产品进展充分展示了其在这一尖端抗癌疗法领域的领先地位,也增强了市场对科济药业长期增长潜力的看好预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.